2024-03-31-accounts - Bath Institute For Rheumatic Diseases

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

ANNUAL REPORT AND ACCOUNTS 31 March 2024

Company Registration Number 02908933 Charity Registration Number 1040650

Trustees’ Annual Report for the year ended 31 March 2024

Contents	Page
Charity information		1
Trustees’ Annual Report		2
Statement of directors’ responsibilities		12
Independent Examiner Report		14
Funds Statements:-
Statement of Financial Activities	Statement of Financial Activities	16
Prior Year statement		17
Statement of total recognised
gains and losses		18
Income and Expenditure account		19
Balance sheet		20
Notes to the accounts		22

Charity information

The Trustees present their Report and Accounts for the year ended 31 March 2024, which also comprises the Directors’ Report required by the Companies Act 2006.

The charity name

The legal name of the charity is:Bath Institute for Rheumatic Diseases. The charity is also known by its operating name, BIRD.

The charity’s areas of operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1040650. The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:- Department D1

Wolfson Building, Royal United Hospital Bath, BA1 3NG

Telephone 01225 336363

BIRD@birdbath.org.uk www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in office for the period covered by the report:

Chris Johns Dr Amanda Mackenzie Prof Neil McHugh Prof Bernie Morley emeritus - Chair Shane O’Reilly Prof Raj Sengupta Jim Sherwin Linda Snelus Dr William Tillett

Trustees’ Annual Report for the year ended 31 March 2024

Objects and activities of the charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

Strategy

We continue to follow our new strategy with the central purpose of balancing reliance on investment performance over the long term with more grant and donor fundraising, which in turn requires a raised profile and clearer articulation of impact.

A recent stakeholders survey highlighted the progress we have made with comments such as “BIRD is now more outgoing and focused on engagement and education of staff and patients” and “overall I think that the organisation now reaches far more people than in the past and the number research grants given has increased”.

Highlights

Shortlisted for Charity of the Year in the South West Business Awards
Reaching the 20,000 milestone in listens to BIRD podcasts for patients
BIRD attending the British Society of Rheumatologists conference for the second time to highlight our work
BIRD organising the second Research Showcase event in Bath
BIRD producing six new videos for use in the reception area of the Royal National Hospital for Rheumatic Diseases
BIRD being placed on the Chancellor’s Roll of Honour at the University of Bath (see below)

We finish the financial year with £1,791,638 in funds, up from £1,676,599 at the same point last year, reflecting good growth in BIRD’s investment funds since income totalled £106,886 but expenditure £238,682. In total BIRD awarded £66,406 in grants and bursaries to clinician researchers and early career researchers and spent £59,054 on patient and public engagement.

Grants awarded for research In total, £63,551 for research was BIRD funds research projects in rheumatic awarded diseases which:

£19,950 to Dr Jessica Ellis for a project about the Utility of a novel imaging biomarker for the identification of excess cardiovascular risk in auto-immune rheumatic diseases.
Help to promote and advance medical knowledge
Improve treatments for patients
Encourage collaboration between clinicians and research scientists

We hope this project will improve the identification of cardiovascular disease in rheumatology patients. It will use existing CT scans from lupus and scleroderma patients, and measure inflammation on these scans. This project will then see whether it can identifiy increased cardiovascular risk using existing tools. It will also use a large national database of scans, to see whether rheumatology patients are more likely to have this inflammation.

Supports the next generation of researchers into bone and joint diseases

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £20,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

£19,953 to Dr Amanda Mackenzie for a project promoting the regression of angiogenesis in the pathology of rheumatoid arthritis. Rheumatoid arthritis is a common disease, affecting more than 400.000 in the UK. Blood vessels grow into joints during the progression of the disease. This growth makes the damaging inflammation worse and increases joint pian. This project aims to improve treatments for patients with rheumatoid arthritis and promote collaboration between clinical and research scientists.

It aims to promote and advance medical science, pump-priming research, help researchers in the early stages of their careers, help clinicians to be research active, encourage collaborations between clinicians and research scientists, and ensure patients are involved in research.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

£2720 to Fionnula McMorrow For knowledge exchange of IP-MS method at KU Leuven. As part of a PhD this project involves using and adapting highly specialised laboratory techniques to try and find new autoantibodies in the blood of children with rare rheumatic diseases called myositis and systemic sclerosis,

Since 2016 BIRD has funded over 26 projects, with over 600 patients involved in a meaningful way, helping to advance medical science, with grants generating at least 20 academic publications so far.

Trustees’ Annual Report for the year ended 31 March 2024

£20,000 to Dr Joseph Page for assessing the Vascular Endothelium in Systemic sclerosis associated Pulmonary hypertension to improve Early and Rapid diagnosis (VESPER)

Pulmonary arterial hypertension (PAH) and progressive fibrotic interstitial lung disease (ILD) are common and sadly fatal complications of Systemic Sclerosis. The study will invite patients with and without systemic sclerosis to provide a blood test. The researchers will compare the results between patients with and without systemic sclerosis. It will also look to see whether these tests match with right heart catheterisation results in patients who have this test done as part of their routine care. If we can improve our understanding of blood vessel damage in systemic sclerosis, it may help us to predict which patients are more at risk of developing PAH, and commence timely treatment. It may help provide more accurate non-invasive tests to detect PAH.

£928 to the RNHRD Research Nurses for a Laptop

Bursaries

Building on the recent success of early career researchers BIRD awarded £2755 for bursaries to attend BSR and EULAR, and the World Congress on Osteoporosis in early 2024.

This is to encourage health professionals based in the Royal National Hospital for Rheumatic Diseases (RNHRD) to attend these key national and international conferences as part of BIRD’s mission is to encourage clinical staff to be research-active and to maintain the RNHRD’s reputation for research excellence.

“The Bristish Society for Rhuematology (BSR) conference, is a key event in my work calendar. Every year I meet new people and develop contacts with colleagues around the UK. Lots of action points and things for us to review and develop further in our service here in Rheumatology Therapies”.

“Thanks so much for BIRD support to attend my first BSR meeting. It was great to hear from leading clinicians and researchers in the field of AxSpA and axial PsA, and also be able to attend other sessions covering a range of the rheumatology field. Quite mind-blowing at times”.

My experience at BSR was fabulous. I was able to discuss complex cases with my colleagues and also saw many interesting educational abstracts. This gave me further ideas on how to innovate our system but also enabled me to enhance my research work’’.

For the second time BIRD took a stand at the annual British Society for Rheumatology Conference in Manchester to showcase the Patient Engagement programme. This was to promote and network for further patient engagement opportunities.

BIRD led and organised the RNHRD’s second Research Showcase Event at the Bath Royal Literary and Scientific Institute in March 2024 together with Royal United Hospital Bath, and the University of Bath.

Five Consultants and early career researchers from the RNHRD gave talks on their research and showed 10 research posters for 60 members of the general public. The feedback was again very positive and BIRD plan to make the Research Showcase an annual event.

“All of the talks were engaging. It is wonderful to listen to our doctors so full of passion for their specialism and wanting to provide the best for their patients”.

“I found the talks all very informative, very interesting and very beautifully presented by the professionals. I am very grateful to have attended and would love to come to other similar events. I hope that there will be more”.

“We really enjoyed the speakers and their enthusiasm into their specialist research. It was wonderful to see their passion and desire to find out more around their specialism and their desire to pass on their findings for those in their care now and in the future”.

Trustees’ Annual Report for the year ended 31 March 2024

BIRD’s education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education and Research Trust. The programme was attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

BIRD provided the administration support including the accreditation and sponsorship where necessary, for educational events reaching 415 healthcare professionals Each of the training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

The programme for 2023/24 included the following events:

One Rheumatology Research @ Bath meeting was held, bringing together researchers at the University and clinicians at the hospital to update one another on two new projects at a time.

Two Bath & Bristol Bone meetings were held in May and November 2023 for consultants and clinical staff.

The South West Axial Spondyloarthritis Group was held in November 2023 for consultants and clinical staff.

Two South West CTD & Vasculitis meetings

were held in March & September 2023 for consultants and clinical staff.

Two Primary Care Rheumatology Update

afternoons were held in April 2023 and March 2024 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

Knowledge Exchange with Stoke UHNM

NHS Trust & RNHRD – BIRD provided the organisation and admin support for the Stoke visit to Bath. Over the two-day event each Trust shared their practices and procedures for the Management of Spondyloarthritis.

Qualitative feedback collected from some of the sessions showed that participants rated talks either ‘excellent’ or ‘good’ with most comments finding the training “helpful” and a useful update;

“The hybrid option for meetings is really valuable and great to see so many attendees online. Great selection of speakers at these events, with fantastic external speakers. Good to see some younger investigators given chance to present and raise their profiles within the region.”

“These are always great meetings - all presentations excellent and very useful discussion. The meeting was very well organised and chaired.”

The Education Programme was led by Dr Andrew Allard, consultant rheumatologist, and Fran Staples, Senior Administrator BIRD.

The Patient and Public Engagement Programme

The Programme vision is to help more patients to be involved in research and deepen their understanding of Rheumatic Diseases, the latest research and treatment. With the twin aims of:

1. Patients have a deeper knowledge of

Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals

2. Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Led by patient engagement expert Mel Brooke and supported by Fran Carroll, the programme has continuously evolved and developed around patient audience needs . It provides opportunities for them to connect, learn and share through a flexible and innovative mix of media.

Podcasts - covering a range of rheumatology conditions, these now reach thousands of patients and their families, across the country (and beyond) which we promote heavily on social media.

Over the year Mel Brooke produced another 10 new podcasts bringing the library to 58 and achieving an amazing total of 23,559 listens .

New topics covered were Gout, Myositis, new BSR guidelines, Psoriatic Arthritis (PsA), updated NICE guidelines on Osteo Arthritis Nutrition, Pain and Mental Health

Webinars - were developed, providing l ive events online that give patients access to consultants and experts’ presentations and the opportunity to ask questions. 577 patients attended six webinars on Axial Spondyloarthritis, PsA and Osteoporosis.

“A very useful webinar covering a great deal of research explained in a digestible way.”

“I’ve learnt some things today which have completely changed my view on my disease activity and care alongside that.”

“So grateful for these webinars, the knowledge shared, and opportunity to ask questions.

100% of patients who attended the Osteoporosis webinar would recommend others to attend.

Trustees’ Annual Report for the year ended 31 March 2024

Research - patients tell us they are keen to ‘give back’ and get involved in research, mainly through taking part in surveys and questionnaires circulated but also through focus groups, workshops and other participation. Over 188 patients were involved in research during the year.

Patient Research Panel – 28 committed enthusiasts provided feedback on survey design and research opportunities to academic and clinical researchers during the year

Some highlights of the work involving patients in research over the last year include

helping the RUH Research Database Team to engage patients to help test an online survey designed to support the Rheumatology Advice Line.
supporting a researcher to share a call for people to participate in a Fibromyalgia Focus Group
guiding the patient research panel to lay review a Patient Information Leaflet for a new tissue bank relating to Systemic Autoimmune Rheumatic Diseases (SARDs)
helping a researcher find participants for a PsA workshop in biologics, set up and co-host the online evening workshop, help capture and summarise the qualitative data input.
helping to share a survey to gather patient opinions and, later, help again to find participants to attend a workshop (research to develop the concept for a new tool to support hand exercise and self-manage medications in RA)
helping the Rheumatology Research Team at the RUH to find volunteers to participate in a ~~ooo~~ research study day in PsA • helping a historical writer find people to share lived experience of Lupus for research for their book.WW

• helping share an opportunity for people with PsA to participate in a project aimed at helping improve the patient and public engagement in clinical trials.

• helping to find patients to participate in workshops about PIFU (Patient Initiated Follow Up)

helping to review patient information documents for an observational study on use of a medication in axSpA and PsA (through the Patient Research Panel)
helping a researcher shape the questions for a research survey in fatigue and exercise in axSpA and, later, share it with the BIRD patient network to gather patient insights.

Awareness raising

The reach of BIRD continued to expand through ongoing investment in Facebook, Instagram, X and LinkedIn, with over 334,000 people getting the opportunity to see a BIRD advertisement for podcasts. BIRD’s subscriber database grew by 34% across Twitter, Facebook, Mailchimp and LinkedIn.

Particular success was achieved in celebrating the 20,000 listens to podcasts milestone, achieving good coverage in local press and BBC radio. This led to BIRD being nominated in the South West Business awards as Charity of the year.

BIRD also produced six information videos to be used in the reception at the RNHRD

–these covered various topics including an introduction to the RNHRD, Biologics and a short introduction to the research department’s work.

BIRD was also delighted to be placed on the Chancellors Roll of Honour at the University of Bath, this recognises the support BIRD has given the University over the years.

grants from Effort spent in seeking to attract pharmaceutical companies for the Patient Engagement programme was rewarded with £22,000 in grants and sponsorship from Eli Lily and Company and UCB. This was largely due to the excellent performance of the podcasts and advertising them widely on social media, which attracted thousands of listeners.

The following people and trusts gave for which significant donations and legacies BIRD is very grateful , and their n ames were added to the Benefactors Board , recently moved to the entrance of the Royal National Hospital for Rheumatic Diseases

Erika Wiesenmueller-Potter and Barry Potter Mary Dixon Medlock Charitable Trust Hospital Saturday Fund Renishaw

Many others made donations to BIRD over the year, often after reading news or research and developments in BIRD’s newsletter. Thank you to all for the vital support.

The main achievements and performance of the charity in terms of public benefit

The total amount of grants and bursaries awarded for research into rheumatic diseases was £66,406

415 professionals attended BIRD

training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics.

100% of patients who attended the Osteoporosis webinar would recommend others to attend future webinars

15 opportunities to participate in research,

26 members of the were offered to patients, patient research panel responded to 5 new research opportunities.

90% of the 60 attendees to the Research Showcase said they were more likely to get involved in research.

188 Patients involved in research

Awareness raising continued to grow through advertising, e-newsletter engagement and stakeholder relations with the University and the Hospital.

34% growth in subscibers

BIRD recruited new committee members to the finance and research committees.

Overall, the charity’s beneficiaries: scientific academia and patients, carers and their families benefitted from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.

Trustees’ Annual Report for the year ended 31 March 2024

Structure, governance and management of the charity

Bankers

Unity Trust Bank, 9 Brindley Place, Birmingham B1 2HB

The governing body is the Council of Management made up of 9 trustees. The chair is now Professor Bernie Morley emeritus, the Council of Management meets triannually.

CCLA Investment Management Ltd, COIF Charity Funds, 1 Angel Lane, London EC4R 3AB

Three committees report to the Council of Management.

Solicitors

Stone King, 13 Queen Square, Bath BA1 2HJ

There are the triannual Finance Committee , chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns, Linda Snelus and new member Bernard Fairhurst; the biannual Research Committee, chaired by Professor Bernie Morley emeritus, members are Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr Sarah Skeoch, Dr Paula Smith-resigned and has been replaced by Dr Abbie Jordan , Dr Theresa Smith, Frank Sweeting and Dr Sarah Tansley; and the triannual Education & Engagement Committee, chaired by Shane O’Reilly, members are Dr Andrew Allard, Patricia Mattinson and Jessie Naish. All committees are supported by relevant contract staff in attendance.

Accountants

DR Hicks, Chartered Accountants, 107 Penn Hill Road, Bath BA1 3RU

Financial review

The financial position of the charity at 31 March 2024 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

		2024	2023
		£	£
Net income		115,039	(142,906)
Unrestricted Revenue Funds available for the
general purposes of the charity	1,754,967		1,631,034
Designated Revenue Funds		18,478	26,886
*Total Unrestricted Funds*	~~1,773,445~~		~~1,657,920~~
Restricted Revenue Funds		18,193	18,679
~~Total Funds~~	~~1,791,638~~		~~1,676,599~~

The Finance Committee, on behalf of Council ensured BIRD’s investments maximised the funds available for furthering BIRD’s charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.

BIRD’s reserves policy is to

hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity’s assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide

sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a ‘balanced’ return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity’s aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity’s reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised.

Dividends and interest are paid away on a quarterly basis.

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £80,000, depending on the quality of applications received. It will encourage clinicians to undertake research and early stage career researchers with their development through enhanced numbers of bursaries for conference attendance.

BIRD will continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers to work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention reamins to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. BIRD will work on a strategy to achieve that during the year ahead.

Next year BIRD will undertake a recruitment exercise for new Trustees and committee members as part of good succession planning.

As part of its 50th Anniversary in 2025 BIRD will maximise engagement with the public, patients and stakeholders.

Trustees’ Annual Report for the year ended 31 March 2024

Details of The Independent Examiner

Tom Case

Member of The Institute of Chartered Accountants in England and Wales 20 Goodwood Way Cepen Park South Chippenham Wiltshire SN14 0SY

Statement of the Directors’ and Trustees’ Responsibilities

The charity’s trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
select suitable accounting policies and apply them consistently;
make judgements and estimates that are reasonable and prudent;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity’s transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees’ report, and the statutory responsibility of the Independent Examiner in relation to the Trustees’ report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Method of preparation of accounts - Small company provisions.The financial statements are set out on pages 16 to 35.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 20 September 2024.

Professor Bernie Morley emeritus Chair

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2024

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2024

I report to the Trustees on my examination of the financial statements of the charitable company on pages 15 to 34 for the year ended 31 March 2024 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 21.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company’s Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit

requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:- a) examine the financial statements of the charity under Section 145 of the Act;

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner’s Statement and scope of work undertaken

I report in respect of my examination of the charity’s financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider

in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide.

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner’s Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;
This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;
and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-
accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;
the financial statements do not accord with those records; or
the financial statements do not comply with he applicable requirements concerning tthe form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a ‘true and fair’ view, which is not a matter considered as part of an independent examination;
have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-

Tom Case - Independent Examiner

The Institute of Chartered Accountants in England and Wales

20 Goodwood Way Cepen Park South Chippenham Wiltshire SN14 0SY

This report was signed on 20 September 2024.

Statement of Financial Activities for the year ended 31 March 2024

	SORP	Current	Current	Current	Prior
	Ref	Unrestricted	Restricted	Total Funds	Total Funds
		Funds	Funds
		2024	2024	2024	2023
		£	£	£	£
Income & Endowments from:
Donations & Legacies	A1	38,464	-	38,464	52,340
Charitable activities	A2	24,550	75	24,625	66,645
Investments	A4	43,797	-	43,797	44,462
~~Total income~~	~~A~~	~~106,811~~	~~75~~	~~106,886~~	~~163,447~~
Expenditure on:
Charitable activities	B2	238,208	472	238,680	244,037
~~Total expenditure~~	~~B~~	~~238,208~~	~~472~~	~~238,680~~	~~244,037~~
Net gains/(losses) on investments	Net gains/(losses) on investments B4	246,833	-	246,833	(62,316)
Net income for the year		115,436	(397)	115,039	(142,906)
Transfers between funds	C	89	(89)	-	-
Net income after transfers	A-B-C	115,525	(486)	115,039	(142,906)
Net movement in funds		115,525	(486)	115,039	(142,906)
Reconciliation of funds:-	E
Total funds brought forward		1,657,920	18,679	1,676,599	1,819,505
~~Total funds carried forward~~		~~1,773,445~~	~~18,193~~	~~1,791,638~~	~~1,676,599~~

The ‘SORP Ref’ indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts. All activities derive from continuing operations

The notes attached on pages 22 to 35 form an integral part of these accounts.

Analysis of prior year total funds as required by paragraph 4.2 of the SORP

	SORP	Prior Year	Prior Year	Prior Year	Prior Year
	Ref	Unrestricted	Restricted	Total Funds	Total Funds
		Funds	Funds
		2023	2023	2023
		£	£	£
Income & Endowments from:
Donations & Legacies	A1	52,340	-	52,340	52,340
Charitable activities	A2	66,495	150	66,645	66,645
Other trading activities	A3	-	-	-	-
Investments	A4	44,462	-	44,462	44,462
Other	A5	-	-	-	-
~~Total income~~	~~A~~	~~163,297~~	~~150~~	~~163,447~~
Expenditure on:
Raising funds	B1	-	-	-	-
Charitable activities	B2	243,443	594	244,037	244,037
Other	B3	-	-	-	-
Tax on surplus on ordinary activities B3	Tax on surplus on ordinary activities B3	-	-	-	-
Other taxation	B3	-	-	-	-
~~Total expenditure~~	~~B~~	~~243,443~~	~~594~~	~~244,037~~
Net gains/(losses) on investments	B4	(62,316)	-	(62,316)
Net income for the year		(142,462)	(444)	(142,906)
Transfers between funds	C	2,085	(2,085)	-	-
Net income after transfers		(140,377)	(2,529)	(142,906)
Net movement in funds		(140,377)	(2,529)	(142,906)
Reconciliation of funds:-	E
Total funds brought forward		1,799,804	19,701	1,819,505
~~Total funds carried forward~~		~~1,659,427~~	~~17,172~~	~~1,676,599~~

All activities derive from continuing operations

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement

The notes attached on pages 22 to 35 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2024

Statement of Total Recognised Gains and Losses for the year ended 31 March 2024

		2024	2023
		£	£
	(Deficit)/Surplus for the year :-
Net excess of income over expenditure from operations before tax	Net excess of income over expenditure from operations before tax	(131,794)	(80,590)
	*Income from operations before tax in the Statement of Financial Activites* (131,794)	(131,794)	(80,590)
Realised (losses)/gains on investments	Realised (losses)/gains on investments	-	(710)
	*Surplus as shown in the Income and Expenditure account*	(131,794)	(81,300)
Unrealised (losses)/gains on investments		246,833	(61,606)
Net Movement in funds before taxation		115,039	(142,906)
~~Funds generated in the year as shown on Statement of Financial Activities 115,039~~		~~Funds generated in the year as shown on Statement of Financial Activities 115,039~~	~~(142,906)~~

Income and Expenditure Account for the year ended 31 March 2024 as required by the Companies Act 2006

Income and Expenditure Account for the year ended 31 March 2024 as required by the Companies Act 2006	Income and Expenditure Account for the year ended 31 March 2024 as required by	Income and Expenditure Account for the year ended 31 March 2024 as required by
	2024	2023
	£	£
*Income*
Income from operations	63,089	118,985
Realised gains/(losses) on investments	-	(710)
Investment income
Income from investments, other than interest receivable	43,797	44,462
Gross income in the year before exceptional items	106,886	162,737
~~Gross income in the year including exceptional items~~	~~106,886~~	~~162,737~~
*Expenditure*
Charitable expenditure, excluding depreciation and amortisation	237,788	243,311
Depreciation and amortisation	430	276
Governance costs	462	450
~~Total expenditure in the year~~	~~238,680~~	~~244,037~~
Net income before tax in the financial year	(131,794)	(81,300)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(131,794)	(81,300)
~~Retained surplus for the f~~i~~nancial year~~	~~(131,794)~~	~~(81,300)~~

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity’s activities.

The notes attached on pages 21 to 34 form an integral part of these accounts.

Balance Sheet as at 31 March 2024

Balance Sheet as at 31 March 2024

	Note	SORP	2024	2023
		Ref	£	£
Fixed assets	A
Tangible assets Investments held as fixed assets	9 10	A2 A4	1,786 1,871,796	667 1,674,963
Total fixed assets Current assets		B	1,873,582	1,675,630
Debtors	12	B2	5,774	9,628
Cash at bank and in hand		B4	44,602	48,995
Total current assets			50,376	58,623
Creditors: amounts falling due within one year	13	C1	(132,320)	(57,654)
Net current assets			(81,944)	969
~~The total net assets of the charity~~			~~1,791,638~~	~~1,676,599~~
The total net assets of the charity are funded by the funds of the charity, as follows:-		The total net assets of the charity are funded by the funds of the charity, as follows:-	The total net assets of the charity are funded by the funds of the charity, as follows:-
Restricted funds
Restricted Revenue Funds	17	D2	18,193	18,679
Unrestricted Funds
Unrestricted Revenue Funds	17	D3	1,754,967	1,631,034
Designated Funds
Designated Revenue Funds	17	D3	18,478	26,886
~~Total charity funds~~			~~1,791,638~~	~~1,676,599~~

The ‘SORP Ref’ indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

James Sherwin

Trustee and Chair of the Finance Committee Approved by the board of trustees on 20 September 2024

The notes attached on pages 22 to 35 form an integral part of these accounts.

Notes to the Accounts for the year ended 31 March 2024

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and ‘FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity’s jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material uncertainites about the charity’s ability to continue as a going concern.

Risks and future assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabiltities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is

received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only

when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder’s right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the

Notes to the Accounts for the year ended 31 March 2024

financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery 20 % reducing balance

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in

accordance with the guidance given in the SORP.

Financial instruments including cash and

bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes.

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law.

There are no endowment funds.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

5 Net surplus before tax in the financial year

3 Winding up or dissolution of the charity

The net surplus before tax in the financial year is stated after charging:-

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

represented by the accumulated fund shall be Depreciation of owned fixed assets: transferred to some other charitable body or 2024 2023 bodies having similar objects to the charity. £ £ £430 £ 276 4 Significance of financial instruments to the charity’s position

There are no significant implications of financial instruments to the charity’s financial position or performance.

Notes to the Accounts for the year ended 31 March 2024

6 Investment gains

6 Investment gains
	Current year		Current year	Current year	Current year Prior Year
	Unrestricted		Restricted	Total Funds	Total Funds Total Funds
	Funds		Funds
	2024		2024	2024	2024
*Realised gains/(losses)*
Listed investments		-	-	-	- (710)
Unrealised gains /(losses) and writing
*down of carrying values*
Listed investments - Unrealised		246,833	-	246,833	(61,606)
~~Total unrealised gains/(losses) etc~~		~~246,833~~	~~-~~	~~246,833~~	~~246,833~~ ~~(61,606)~~
Total realised and unrealised gains		246,833	-	246,833	246,833 (62,316)
All the gains and losses in the prior year was unrestricted.
*Prior year*
	Prior Year		Prior Year	Prior Year
	Unrestricted		Restricted	Total
	Funds		Funds	Funds
	2023		2023	2023
		£	£	£
*Realised gains/(losses)*
Listed investments		(710)	-	(710)
~~Total realised gains/(losses)~~		~~(710)~~	~~-~~	~~(710)~~
*Unrealised gains /(losses) and writing down*	*Unrealised gains /(losses) and writing down*
*of carrying values*
Listed investments - Unrealised	(61,606)		-	(61,606)
~~Total unrealised gains/(losses) etc~~	~~(61,606)~~		~~-~~	~~(61,606)~~
Total realised and unrealised gains	(62,316)		-	(62,316)

7 Staff costs and emoluments

7 Staff costs and emoluments
*Labour costs*	2024	2023
	£	£
Gross salaries, labour and related costs	133,060	119,611
	~~133,060~~	~~119,611~~

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

8 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

9 Tangible fixed assets

9 Tangible fixed assets
*Current Year*	Plant &		Motor	Total
	Machinery		Vehicles
		£	£	£
Cost
At 1 April 2023	11,940		-	11,940
Additions		1,549	-	1,549
~~At 31 March 2024~~	~~13,489~~		~~-~~	~~13,489~~
Depreciation
At 1 April 2023	11,273		-	11,273
Charge for the year		430	-	430
~~At 31 March 2024~~	~~11,703~~		~~-~~	~~11,703~~
Net book value
At 31 March 2024		1,786	-	1,786

~~At 31 March 2023~~		~~667~~	~~-~~	~~667~~

Notes to the Accounts for the year ended 31 March 2024

10 Investments held as fixed assets

	Investments in	Listed	Other Classes	Other Classes Total
	subsidiaries	Investments	of Investment
	£	£	£	£
Carrying values of investments
At 1 April 2023	2	1,674,961	-	1,674,963
Revaluation at 31 March 2024	-	246,833	-	246,833
Disposals	-	(50,000)	-	(50,000)
~~At 31 March 2024~~	~~2~~	~~1,871,794~~	~~-~~	~~1,871,796~~

11 Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company’s investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary’s activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the nine years ending 31st March 2024.

A summary of the unaudited financial statements of the subsidiary is :-

12 Debtors

12 Debtors
		2024	2023
		£	£
Trade Debtors		5,513	8,767
Payments and accrued income		261	861
		~~5,774~~	~~9,628~~
13 Creditors: amounts falling due within one year
		2024	2023
		£	£
Trade creditors		42,542	14,325
Accruals		9,900	6,600
Other creditors		79,878	36,729
		~~132,320~~	~~57,654~~
14 Income and Expenditure account summary
		2024	2023
		£	£
At 1 April 2023 1,738,205			1,819,505
Surplus after tax for the year	(131,794)		(81,300)
~~At 31 March 2024~~ ~~1,606,411~~			~~1,738,205~~

15 No related party transactions

There were no transactions with related parties in the year.

A summary of the unaudited financial statements of the subsidiary is :-
	2024	2023
	£	£
*Assets and Funds*
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
~~Aggregate amount of funds~~	~~(547)~~	~~(547)~~
*Profit and Loss*
*Net profit for the year before tax*	-	-
~~Net prof~~i~~t for the year after tax and Gift Aid~~	~~-~~	~~-~~
Funds retained within charitable subsidiaries
	2024	2023
	£	£
The funds retained within the trading subsidiary and included
within the restricted funds in the notes to these accounts are:-	-	-

Notes to the Accounts for the year ended 31 March 2024

16 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2024	Unrestricted	Designated	Restricted	Total
	Funds	Funds	Funds	Funds
	£	£	£	£
Tangible Fixed Assets	1,786	-	-	1,786
Investments at valuation:-
Fixed asset investments	1,871,796	-	-	1,871,796
Current Assets	13,705	18,478	18,193	50,376
Current Liabilities	(132,320)	-	-	(132,320)
	~~1,754,967~~	~~18,478~~	~~18,193~~	~~1,791,638~~
At 1 April 2023	Unrestricted	Designated	Restricted	Total
	Funds	Funds	Funds	Funds
	£	£	£	£
Tangible Fixed Assets	667	-	-	667
Investments at valuation:-
Fixed asset investments	1,674,963	-	-	1,674,963
Current Assets	13,058	26,886	18,679	58,623
Current Liabilities	(57,654)	-	-	(57,654)
	~~1,631,034~~	~~26,886~~	~~18,679~~	~~1,676,599~~

17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

17 Change in total funds over the year as shown in Note 16 , analysed by individual funds	17 Change in total funds over the year as shown in Note 16 , analysed by individual	17 Change in total funds over the year as shown in Note 16 , analysed by individual	17 Change in total funds over the year as shown in Note 16 , analysed by individual	17 Change in total funds over the year as shown in Note 16 , analysed by individual
	Funds brought Movement in	Funds brought Movement in	Funds brought Movement in Transfers Funds carried	Transfers Funds carried
	forward from	funds in	between	forward to
	2023	2024	funds in 2024	funds in 2024 2025
		See Note 18 See Note 19	See Note 18 See Note 19
	£	£	£	£
*Unrestricted and designated funds:-*
Unrestricted Revenue Funds	1,631,034	115,436	8,497	1,754,967
Designated Revenue Funds	26,886	-	(8,408)	18,478
~~Total unrestricted and designated funds~~	~~1,657,920~~	~~115,436~~	~~89~~	~~1,773,445~~
*Restricted funds:-*
Restricted - CRPS Conference	1,121	-	-	1,121
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Arthritis Grand Challenge	67	-	(67)	-
Restricted - Metabolic Bone Disease	3,346	(397)	(22)	2,927
~~Total restricted funds~~	~~18,679~~	~~(397)~~	~~(89)~~	~~18,193~~

~~Total charity funds~~	~~1,676,599~~	~~115,039~~	~~-~~	~~1,791,638~~

18 Analysis of movements in funds over the year as shown in Note 17

			Other
	Income	Expenditure	Gains &	Movement
			Losses	in funds
	2024	2024	2024	2024
	£	£	£	£
*Unrestricted and designated funds:-*
Unrestricted Revenue Funds	106,811	(238,208)	246,833	115,436
*Restricted funds:-*
Restricted - Metabolic Bone Disease	75	(472)	-	(397)
	~~106,886~~	~~(238,680)~~	~~246,833~~	~~115,039~~

19 Details of transfers between

19 Details of transfers between
*The transfers shown in note 17 above are:-*	2024
	£
To/(from) Unrestricted Revenue Funds in accordance with
the accounting policy ‘Accounting for capital grants and
fixed asset funds’.	8,497
To/(from) Designated Revenue Funds	(8,408)
To/(from) Restricted Revenue Funds	(89)
~~Net transfers~~	~~-~~

20 The purposes for which the funds

Unrestricted and designated funds:-

Unrestricted Revenue Funds	These funds are held for the meeting the objectives of the charity, and to provide
	reserves for future activities, and , subject to charity legislation, are free from all
	restrictions on their use.
Designated Revenue Funds	Funds specific for this purpose.
*Restricted funds:-*
Restricted Revenue Funds	Funds specific for this purpose.

21 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Notes to the Accounts for the year ended 31 March 2024

22 Donations, Grants and Legacies

22 Donations, Grants and Legacies
	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year
	Unrestricted	Unrestricted Restricted	Total	Total
	Funds	Funds	Funds	Funds
	2024	2024	2024	2023
	£	£	£	£
Donations and gifts from individuals
Donations	38,462	-	38,462	52,301
~~Total donations and gifts from individuals~~	~~38,462~~	~~-~~	~~38,462~~	~~52,301~~
Legacies receivable
Legacies receivable	2	-	2	39
~~Total legacies receivable~~	~~2~~	~~-~~	~~2~~	~~39~~
Total Donations, Grants and Legacies
~~Total Donations, Grants and Legacies A1~~	~~38,464~~	~~-~~	~~38,464~~	~~52,430~~

Notified of a share of the estate of Hedley John Stephens yet to be realised.

23 Income from charitable activities - Trading Activities

*Current year*	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year
	Unrestricted	Unrestricted Restricted	Total	Total
	Funds	Funds	Funds	Funds
2024	2024	2024	2023
	£	£	£	£
Primary purpose and ancillary trading
Education income	1,923	75	1,998	43,287
Other and recharged income	105	-	105	1,139
Service charges - BGPERT	17,558	-	17,558	17,561
Service charges - BRIT PACT	4,964	-	4,964	4,658
~~Total Primary purpose and ancillary trading~~	~~24,550~~	~~75~~	~~24,625~~	~~66,645~~

24 Total Income from charitable activities

	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year	Current year Current year Current year Prior Year
*Current year*	Unrestricted	Unrestricted Restricted	Total	Total
	Funds	Funds	Funds	Funds
	2024	2024	2024	2023
	£	£	£	£
Total income from charitable trading	24,550	75	24,625	66,645
~~Total from charitable activities A2~~	~~24,550~~	~~75~~	~~24,625~~	~~66,645~~
Not all the income in the prior year was unrestricted.
Income from charitable activities - Prior Year analysis

	Prior year	Prior year	Prior Year	Prior Year
	Unrestricted		Restricted	Total Funds
*Prior Year*		Funds	Funds
		2023	2023	2023
		£	£	£
Total income from charitable trading		66,495	150	66,645
		~~66,495~~	~~150~~	~~66,645~~
25 Investment income
	Current year Current year Current Year		Current year Current year Current Year	Current year Current year Current Year	Current year Current year Current Year Prior Year
	Unrestricted		Restricted	Total	Total
		Funds	Funds	Funds	Funds
		2024	2024	2024	2023
		£	£	£	£
Dividend Income		43,797	-	43,797	44,462
~~Total investment income A4~~		~~43,797~~	~~-~~	~~43,797~~	~~44,462~~

26 Expenditure on charitable activities - Direct spending

Not all the trading activities in the prior year were unrestricted

*Prior Year*	Prior year	Prior Year	Prior Year
	Unrestricted	Restricted	Total Funds
	Funds	Funds
	2023	2023	2023
	£	£	£
Primary purpose and ancillary trading
Education income	43,287	-	43,287
Other and recharged income	989	150	1,139
Service charges - BGPERT	17,561	-	17,561
Service charges - BRIT PACT	4,658	-	4,658
~~Total Primary purpose and ancillary trading~~	~~66,495~~	~~150~~	~~66,645~~

	Current year Current year Current Year	Current year Current year Current Year	Current year Current year Current Year	Prior Year
	Unrestricted	Restricted	Total	Total
	Funds	Funds	Funds	Funds
	2024	2024	2024	2023
	£	£	£	£
Labour costs - charitable activities	133,060	-	133,060	119,611
Education costs	7,269	472	7,741	42,273
PPE Project costs	2,344	-	2,344	8,545
~~Total direct spending B2a~~	~~142,673~~	~~472~~	~~143,145~~	~~170,429~~

Not all the expenditure in the prior year was unrestricted.

Notes to the Accounts for the year ended 31 March 2024

27 Expenditure on charitable activities- Grant funding of activities

	Current year Current year Current Year	Current year Current year Current Year	Current year Current year Current Year	Prior Year
*Current Year*	Unrestricted	Restricted	Total	Total
	Funds	Funds	Funds	Funds
	2024	2024	2024	2023
	£	£	£	£
Grants made to individuals	63,776	-	63,776	49,739
~~Total grantmaking costs B2c~~	~~63,776~~	~~-~~	~~63,776~~	~~49,739~~

28 Support costs for charitable activities

~~Total grantmaking costs B2c~~ 28 Support costs for charitable activities	~~63,776~~ ~~-~~ 28 Support costs for charitable activities	~~63,776~~ ~~-~~ 28 Support costs for charitable activities	~~63,776~~	~~63,776~~	~~49,739~~
	Current year Current year Current Year		Current year Current year Current Year		Current year Current year Current Year Prior Year
*Current Year*	Unrestricted	Restricted	Total	Total	Total
	Funds	Funds	Funds	Funds	Funds
	2024	2024	2024	2024	2023
	£	£	£		£
*Premises Expenses*
Rent	3,300	-	3,300	3,300	6,000
*Administrative overheads*
Telephone, fax and internet	1,034	-	1,034	1,034	760
Stationery and printing	1,151	-	1,151	1,151	423
Marketing and promotion	14,926	-	14,926	14,926	5,307
Registration and licensing	1,622	-	1,622	1,622	1,068
IT support costs	2,380	-	2,380	2,380	1,867
Sundry expenses	-	-	-	-	720
Recharged expenses	72	-	72	72	1,189
Insurance	547	-	547	547	440
Trustees costs	177	-	177	177	-
Hospitality	472	-	472	472	-
Travel	20	-	20	20	67
*Professional fees paid to advisors other than the auditor or examiner*
Accountancy fees other than
examination or audit fees	4,033	-	4,033	4,033	3,660
Other legal and professional	1,017	-	1,017	1,017	1,526
*Financial costs*
Bank charges	116	-	116	116	116
Depreciation	430	-	430	430	276
~~Total support costs~~	~~31,297~~	~~-~~	~~31,297~~	~~31,297~~	~~23,419~~
	Current year Current year		Current year Current year Prior Year
	Unrestricted	Restricted	Total Funds
	Funds	Funds
	2024	2024	2023
	£	£	£
Recharged expenses *Support costs before reallocation*	595 22,825	594 594	1,189 23,419
~~Total support costs - Prior Year~~	~~22,825~~	~~594~~	~~23,419~~	~~23,419~~

29 Other Expenditure - Governance costs

	Current year Current year Current Year	Current year Current year Current Year	Current year Current year Current Year	Prior Year
*Current Year*	Unrestricted	Restricted	Total	Total
	Funds	Funds	Funds	Funds
	2024	2024	2024	2023
	£	£	£	£
Independent Examiner’s fees	462	-	462	450
~~Total Governance costs~~	~~462~~	~~-~~	~~462~~	~~450~~

All the expenditure in the prior year was unrestricted.

30 Total Charitable expenditure

		Current year Current year Current Year	Current year Current year Current Year	Current year Current year Current Year	Current year Current year Current Year Prior Year
*Current Year*		Unrestricted	Restricted	Total	Total
		Funds	Funds	Funds	Funds
		2024	2024	2024	2023
		£	£	£	£
Total direct spending	B2a	142,673	472	143,145	170,429
Total grantmaking costs	B2c	63,776	-	63,776	49,739
Total support costs	B2d	31,297	-	31,297	23,419
Total Governance costs	B2e	462	-	462	450
~~Total charitable expenditure~~	~~B2~~	~~238,208~~	~~472~~	~~238,680~~	~~244,037~~
		Prior year	Prior Year	Prior Year
		Unrestricted	Restricted	Total Funds
*Prior Year*		Funds	Funds
		2023	2023	2023
		£	£	£
Total direct spending	B2a	170,429	-	170,429
Total grantmaking costs	B2c	49,739	-	49,739
Total support costs	B2d	22,825	594	23,419
Total Governance costs	B2e	450	-	450
~~Total charitable expenditure~~	~~B2~~	~~243,443~~	~~594~~	~~244,037~~

Trustees’ Annual Report for the year ended 31 March 2024

415 2s GRANTS AWARDED \ 7] HEALTH FOR RESEARCH PROFESSIONALS ATTENDING 7@ £63,551 TRAINING | SESSIONS

90% OF THOSE — 15 ATTENDING THE OPPORTUNITIES RESEARCH TO PARTICIPATE IN SHOWCASE SAID RESEARCH THEY WERE MORE OFFERED TO LIKELY TO GET PATIENTS INVOLVED IN eww RESEARCH

20,000 LISTENS TO PODCASTS

ANNUAL REPORT AND ACCOUNTS 31 March 2024

Company Registration Number 0290893338 Charity Registration Number 1040650